Odinwell (ODIN) Q1 2025 earnings summary

Executive summary

• Revenue for Q1 2025 was 1,115 KSEK, down from 1,429 KSEK in Q1 2024; operating loss improved to -1,766 KSEK from -2,017 KSEK year-over-year.

• Net loss after tax was -1,733 KSEK, nearly unchanged from -1,744 KSEK in the prior year period.

• EPS remained at -0.07 SEK, unchanged year-over-year.

Financial highlights

• Cash position at quarter-end was 1,491 KSEK, with an additional 1,830 KSEK in short-term investments.

• Operating cash flow for the quarter was -1,898 KSEK, reflecting continued investment in development.

• Equity ratio (soliditet) was 95% at quarter-end, indicating strong capital structure.

• Monthly operating expenses averaged 869 KSEK, totaling approximately 2.6 MSEK for the quarter.

Outlook and guidance

• Planned start for a clinical pilot study is end of May, pending ethics approval.

• New capital from a rights issue will be used to secure key personnel and expand patent portfolio.

• Broader application of technology and product portfolio expansion are in focus.